ARCHIMED Diagnostics Acquires 60% Stake in ARK Diagnostics

ARCHIMED Acquires Majority Stake in Arkstone Medical Solutions

August 6, 2025

Healthcare Services

ARCHIMED, a healthcare-focused private equity firm, has acquired a majority stake in Arkstone Medical Solutions, a provider of AI/ML-driven clinical decision support and antimicrobial stewardship tools. The investment will support Arkstone's product development, global expansion and R&D to accelerate adoption of its OneChoice Report in laboratories and healthcare providers worldwide.

ARCHIMED Acquires BioVendor Group

March 11, 2025

Medical Devices

ARCHIMED, a Europe-focused private equity firm specializing in healthcare, has acquired BioVendor Group, a Brno-headquartered developer and manufacturer of in‑vitro diagnostics and immunoassays. ARCHIMED will partner with existing management to accelerate internationalization, product innovation and commercial expansion as part of its MED III fund's diagnostics investment strategy.

ArchiMed Acquires Natus Medical Incorporated

July 21, 2022

Medical Devices

ArchiMed, through its MED Platform II fund, completed a take‑private acquisition of Natus Medical Incorporated, with Natus shareholders receiving $33.50 per share. ArchiMed said it will internationalize and grow Natus' neurodiagnostics product portfolio, reinforce R&D, and pursue complementary bolt‑on acquisitions.

ARCHIMED Acquires Majority Stake in Cube (Cube Biotech)

November 3, 2021

Biotechnology

Transatlantic healthcare private equity firm ARCHIMED has purchased a majority stake in Monheim, Germany-based Cube (Cube Biotech), a specialist provider of high-purity, stable membrane proteins for drug discovery. ARCHIMED will support Cube's US market expansion and broaden its product and service offering organically and via acquisitions while Cube's founding management remain significant shareholders and continue to lead the business.

ARCHIMED Acquires Majority Stake in Germany's Zyto Group

January 12, 2021

Medical Devices

ARCHIMED, through its MED II fund, has acquired a majority stake in the Zyto group — a German developer, manufacturer and distributor of advanced cancer diagnostics, including Zytomed, ZytoVision and 42 Life Sciences. The deal will keep founders and management as significant minority shareholders and is intended to accelerate product innovation, regulatory capabilities and international expansion of the group's precision oncology diagnostics.

ARCHIMED Acquires 75% Stake in ActiGraph

May 18, 2020

Medical Devices

ARCHIMED (ArchiMed) has acquired a 75% stake in ActiGraph in an all-equity transaction, with management retaining 10% and other historic shareholders keeping 15%. The investment will fund ActiGraph's expansion into the regulated drug-development and clinical-trials market, accelerating product, regulatory and commercial capabilities; financial terms were not disclosed.